Results 231 to 240 of about 23,150 (274)
Some of the next articles are maybe not open access.
TREATMENT OF MALIGNANT DISEASE WITH NITROGEN MUSTARD
Annals of Internal Medicine, 1949Excerpt Our purpose in this paper is to summarize the clinical literature on the use of the nitrogen mustards in malignant diseases,—the indications, hazards, effects and side-effects.
D. K. Adler +3 more
openaire +3 more sources
The Nitrogen Mustards: Clinical Use
Radiology, 1948One unexpected and beneficial byproduct of World War II is a method of chemotherapy that undoubtedly is here to stay, at least for some years. This statement refers to the use of nitrogen mustards as palliative agents for certain types of malignant neoplastic processes. While these agents may be said to have failed to measure up to early hopes for them,
openaire +3 more sources
III. Nitrogen Mustard Therapy in the Reticuloses
The British Journal of Radiology, 1951Parenteral administration of the nitrogen mustards leads to changes in the tissues where there are many actively proliferating cells, particularly in the gastrointestinal tract, the lymphatic glands, and the bone marrow. Detailed observations of tissue cultures and mammalian cornea reveal a disturbance of mitosis—an inhibition of the prophase—similar ...
openaire +3 more sources
NITROGEN MUSTARDS AS CANCERINDUCING AGENTS
Journal of the American Medical Association, 1950To the Editor:— The nitrogen mustards, methyl-bis (betachloroethyl) amine hydrochloride (HN2) and tris (beta-chloroethyl) amine hydrochloride (HN3) have been extensively used in the treatment of leukemia and other types of malignant disease (Karnofsky, D. A.; Burchenal, J. H.; Ormsbee, R. A.; Cornman, I., and Rhoads, C.
E. L. Tatum +2 more
openaire +2 more sources
Cyclosporin, leflunomide and nitrogen mustard
Baillière's Clinical Rheumatology, 1995Summary Cyclosporin A (CSA) Cyclosporin inhibits IL-2 release and T-cell activation and, secondarily, affects B-cell function. It also inhibits bone resorption, at least in vitro. This drug's bio-availability averages 25–35% but is highly variable.
openaire +2 more sources
The American Journal of Medicine, 1948 Melflufen: A Next-Generation Nitrogen Mustard
Journal of Clinical Oncology, 2021Sarah A. Holstein +2 more
openaire +3 more sources
Dysgerminoma Treated with Nitrogen Mustard
American Journal of Obstetrics and Gynecology, 1952Lester B. Anderman +2 more
openaire +3 more sources